Patterns and kinetics of T-cell chimerism after allo transplant with alemtuzumab-based conditioning: mixed chimerism protects from GVHD, but does not portend disease recurrence
Authors:
- Koen van BesienKBKoen van Besien
- Alexander DewADAlexander Dew
- Shang LinSLShang Lin
- Loren JosephLJLoren Joseph
- Lucy A. GodleyLGLucy A. Godley
- Richard A. LarsonRLRichard A. Larson
- Toyosi OdenikeTOToyosi Odenike
- Elizabeth RichERElizabeth Rich
- Wendy StockWSWendy Stock
- Amittha WickremaAWAmittha Wickrema
- Andrew S. ArtzAAAndrew S. Artz
- 3 October 2009
- journal article
- research article
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 50 (11) , 1809-1817
Abstract
We analyzed the kinetics of CD3 chimerism in 120 consecutive allogeneic hematopoietic cell transplantation (HCT) recipients receiving alemtuzumab-based conditioning. Fifty-two received fludarabine/melphalan, 44 received fludarabine/busulfan, and 24 received clofarabine/melphalan in addition to alemtuzumab. Post-transplant GVHD prophylaxis consisted of tacrolimus. No prophylactic donor lymphocyte infusion or other interventions were used for mixed donor chimerism (MDC). Bone marrow (BM) and/or peripheral blood (PB) samples were obtained at 30 days, 100 days, 180 days, and 1 year following HCT. On Day 30, 15% of assessable patients had MDC in the CD3 compartment. This had increased to 50% by Day 100, and to 63% by Day 180. MDC predicted for a lower risk of acute (p = 0.08) and particularly of chronic GVHD (p = 0.01). MDC was not associated with subsequent relapse or TRM (p = 0.67 and 0.72, respectively). A decline of more than 15% in CD3 chimerism between Day 30 and Day 180 predicted for a 40% risk of subsequent disease recurrence. The observation of MDC after alemtuzumab conditioning does not by itself constitute a risk factor for relapse and should not be used to guide therapeutic intervention. By contrast, declining donor chimerism between Day 30 and Day 180 is associated with a somewhat increased risk of disease recurrence. The high incidence of MDC after alemtuzumab containing conditioning contributes to the low risk of acute and chronic GVHD.Keywords
This publication has 30 references indexed in Scilit:
- Impact of T Cell Chimerism on Clinical Outcome in 117 Patients Who Underwent Allogeneic Stem Cell Transplantation with a Busulfan-Containing Reduced-Intensity Conditioning RegimenTransplantation and Cellular Therapy, 2008
- Choice and Interpretation of Statistical Tests Used When Competing Risks Are PresentJournal of Clinical Oncology, 2008
- Delayed attainment of full donor chimaerism following alemtuzumab‐based reduced‐intensity conditioning haematopoeitic stem cell transplantation for acute myeloid leukaemia and myelodysplastic syndromes is associated with improved outcomesBritish Journal of Haematology, 2007
- Chimerism does not predict for outcome after alemtuzumab based conditioningBone Marrow Transplantation, 2007
- Early complete donor hematopoietic chimerism in peripheral blood indicates the risk of extensive graft-versus-host diseaseBone Marrow Transplantation, 2005
- Lineage-specific chimaerism after stem cell transplantation in children following reduced intensity conditioning: potential predictive value of NK cell chimaerism for late graft rejectionLeukemia, 2003
- HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignanciesBlood, 2003
- RAPID ESTABLISHMENT OF LONG-TERM CULTURE-INITIATING CELLS OF DONOR ORIGIN AFTER NONMYELOABLATIVE ALLOGENEIC HEMATOPOIETIC STEM-CELL TRANSPLANTATION, AND SIGNIFICANT PROGNOSTIC IMPACT OF DONOR T-CELL CHIMERISM ON STABLE ENGRAFTMENT AND PROGRESSION-FREE SURVIVALTransplantation, 2003
- Chimerism analysis following allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioningBone Marrow Transplantation, 2003
- A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing RiskThe Annals of Statistics, 1988